alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,476–1,500 of 3,821 studies published 2025 (page 60 of 153) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Association of dietary diversity, genetic susceptibility, and the risk of incident dementia: A prospective cohort study

✓ Peer-reviewed alzhub usefulness score 46 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-02-13

Over a median follow-up period of 10.44 years, 725 participants developed incident dementia. 5 key findings →

Participants: 104,572 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Associations of cardiovascular health assessed by life’s crucial 9 with incident cardiovascular disease and dementia: A prospective cohort study

✓ Peer-reviewed alzhub usefulness score 46 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-07-15

Of 289,649 included participants, 137,480 (47.5 %) were male, and the mean age was 56.6 ± 8.1 years. 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Estimation of Machine Learning–Based Models to Predict Dementia Risk in Patients With Atherosclerotic Cardiovascular Diseases: UK Biobank Study

✓ Peer-reviewed alzhub usefulness score 46 out of 100. JMIR Aging 2025-01-20

The findings of this study suggest that predictive modeling could inform patients and clinicians about ASCVD at risk for dementia. 3 key findings →

Participants: 29,561 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Predictive factors for dementia among older adults in South Korea: an interpretable machine learning analysis

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer s Research & Therapy 2025-11-13

Predictive performance was comparable across algorithms, with R² ranging from 0.201 to 0.361, highest in the MCI_All dataset. 5 key findings →

Design: longitudinal study Participants: 4,958 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Classification of AD and bvFTD using neuropsychological and neuropsychiatric variables: a machine learning study

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer s & Dementia 2025-10-01

Among 1616 participants (AD = 1498, bvFTD = 118), all algorithms achieved high accuracy (80% to 90%) and discriminatory ability (AUC = 0.89 to 0.95). 5 key findings →

Participants: 1,616 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Depression and dementia: interrogating the causality of the relationship

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of Neurology Neurosurgery & Psychiatry 2025-01-11

Depression was a strong risk factor for incident dementia with an OR of 1.76 (95% CI 1.63 to 1.90), a relationship which was found to be specific to depression rather than commonly proposed confounders. 5 key findings →

Participants: 557 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Dementia in a resource‐constrained sub‐Saharan African setting: A comprehensive retrospective analysis of prevalence, risk factors, and management at the only neuropsychiatric facility in Northeastern Nigeria

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer s & Dementia 2025-03-01

Of the 1216 cases reported, Alzheimer's disease (60.5%) was the most common subtype, followed by vascular dementia (24.5%). 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of Alzheimer’s and Lewy body disease pathology with basal forebrain volume and cognitive impairment

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer s Research & Therapy 2025-01-27

In a heterogeneous autopsy sample, AD and LB pathology both contribute to cholinergic basal forebrain degeneration whereas hippocampus atrophy is more specifically related to AD pathology. 4 key findings →

Participants: 248 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Differential role of C-terminal truncations on alpha-synuclein pathology and Lewy body formation

✓ Peer-reviewed alzhub usefulness score 46 out of 100. npj Parkinson s Disease 2025-08-26

Alpha-synuclein (aSyn) post-translational modifications (PTM), especially phosphorylation at serine 129 and C-terminal truncations, are highly enriched in Lewy bodies (LB), Lewy neurites, and other pathological aggregates in Parkinson's disease and synucleinopathies. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Glymphatic activity in behavioral variant frontotemporal dementia: Link with vascular function and astrocytic activation

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer s & Dementia 2025-08-01

Glymphatic activity in bvFTD correlated strongly with vascular dysfunction and astrocytic activation, and was associated with brain changes and clinical severity. 5 key findings →

Participants: 61 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Striatal dopaminergic patterns and clinical features in frontotemporal dementia

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Brain Communications 2025-01-01

Moreover, a theoretical model proposes that frontotemporal dementia manifestations result from a deficit in goal-directed behaviour, which may be related to altered dopamine control of the frontostriatal circuitry. 4 key findings →

Participants: 139 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Decision making in frontotemporal dementia: neuropsychological and neuroimaging assessments

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Frontiers in Neuroscience 2025-07-31

Frontotemporal dementia (FTD) is a neurodegenerative disorder primarily affecting the frontal and temporal lobes, leading to significant impairments in executive function, social behavior, and emotional regulation. 3 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Parkinsonism in Alzheimer's disease without Lewy bodies in association with nigral neuron loss: A data‐driven clinicopathologic study

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer s & Dementia 2025-03-01

Among 635 AD patients without LB, 62 (9.7%) presented parkinsonism, which correlated with reduced nigral neuron density (p < 0.01). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Synaptic vesicle endocytosis deficits underlie cognitive dysfunction in mouse models of GBA-linked Parkinson’s disease and dementia with Lewy bodies

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Nature Communications 2025-09-26

GBA is the major risk gene for Parkinson’s disease (PD) and dementia with Lewy bodies (DLB), two common α-synucleinopathies with cognitive deficits. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Differential miRNA expression in neural-enriched extracellular vesicles as potential biomarker for frontotemporal dementia and bipolar disorder

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Neurobiology of Disease 2025-03-08

Behavioral variant of Frontotemporal Dementia (bvFTD) and Bipolar Disorder (BD) share overlapping symptoms, complicating diagnosis. 4 key findings →

Participants: 100 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Identifying gait differences between Alzheimer's disease and dementia with Lewy bodies and their associations with regional amyloid deposition

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer s & Dementia 2025-01-27

The DLB group had reduced stride velocity, step length, and stride width variability, as well as increased double support percentage (%DS) and variability in step length, swing time, and step time compared to the AD and CU groups. 5 key findings →

Participants: 420 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Impact of cardiometabolic conditions on the progression from mild cognitive impairment to dementia: A large cohort study

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer s & Dementia 2025-09-01

During a 7-year median follow-up, type 2 diabetes was associated with the highest risk of all-cause dementia (hazard ratio [HR] 1.18, 95% confidence interval [CI]: 1.06 to 1.31), followed by hypertension and hyperlipidemia. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Development of a neural network-based risk prediction model for mild cognitive impairment in older adults with functional disability

✓ Peer-reviewed alzhub usefulness score 46 out of 100. BMC Public Health 2025-06-02

The results indicated that residence location, alcohol consumption, life satisfaction, depressive symptoms, and education level are key factors influencing the risk of MCI among older adults with functional disability. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Mild cognitive impairment, Alzheimer's disease dementia, and predictors of driving cessation: A 7-year longitudinal prospective study

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of Alzheimer s Disease 2025-04-22

BackgroundPatients with dementia face driving difficulties and, at some point, cease driving. 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed